Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment

Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva Pharmaceuticals, a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce today a collaboration to co-develop and co-commercialize asset TEV’574, currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, two types of inflammatory bowel disease.

Eli Lilly boosts sales forecast by $3bn as diabetes and weight loss drugs propel revenue – Pharmaceutical Technology

Sales of diabetes drug Mounjaro totalled $3.1bn in Q2, compared to $979.7m in the same period last year. Image credit: Shutterstock/ Mohammed_Al_Ali. Eli Lilly has

August 9, 2024

Remote manufacturing assessments: FDA revises draft guidance to include newly expanded powers

The FDA on Friday released newly revised Q&A guidance on how the agency can use voluntary and mandatory remote regulatory assessments to better understand biopharma

January 27, 2024

Social media algorithms are driving the GLP-1 drugs boom – Pharmaceutical Technology

GLP-1 RA drugs are prescribed as treatments for patients with type 2 diabetes, or obesity. Credit: UCG / Getty. A rapid growth in demand for

October 3, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.